Research location
Lleida
Spain
Advertisement
Research activity in Lleida
SpainCureCurrent currently publishes aggregate city-level research activity for this location: 275 trials and 278 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Lleida
275 linked trials · page 1 of 6A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or OverweightNCT07784270 · 2026-08-20 · 1 site observation
RECRUITING
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background DapagliflozinNCT07662135 · 2026-07-06 · 1 site observation
RECRUITING
A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast CancerNCT07401381 · 2026-06-08 · 1 site observation
RECRUITING
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNCT07571109 · 2026-05-05 · 1 site observation
RECRUITING
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNCT07571005 · 2026-05-05 · 1 site observation
RECRUITING
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity ManagementNCT07371585 · 2026-02-18 · 1 site observation
RECRUITING
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT07369011 · 2026-02-10 · 1 site observation
RECRUITING
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)NCT07174336 · 2025-12-22 · 1 site observation
RECRUITING
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant RibociclibNCT07237256 · 2025-12-18 · 1 site observation
RECRUITING
NOPE37: Angiogenic Factors for Managing Term PreeclampsiaNCT07193680 · 2025-12-04 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisNCT07225504 · 2025-11-11 · 1 site observation
RECRUITING
Comprehensive Maintenance Program: a Health Haven for COPD in Lleida.The NAPOLEON Project.NCT07394712 · 2025-10-01 · 1 site observation
RECRUITING
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerNCT06982521 · 2025-08-26 · 1 site observation
RECRUITING
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)NCT06757634 · 2025-07-24 · 1 site observation
RECRUITING
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal SubtypeNCT06486883 · 2025-06-30 · 1 site observation
RECRUITING
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung CancerNCT06712316 · 2025-01-07 · 1 site observation
RECRUITING
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBCNCT06078384 · 2024-12-27 · 1 site observation
RECRUITING
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.NCT06382948 · 2024-12-05 · 1 site observation
RECRUITING
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerNCT06369285 · 2024-11-19 · 1 site observation
RECRUITING
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)NCT06692738 · 2024-11-18 · 1 site observation
RECRUITING
Open-Label Study of BBO-10203 in Subjects With Advanced Solid TumorsNCT06625775 · 2024-10-29 · 1 site observation
RECRUITING
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceNCT06492616 · 2024-09-27 · 1 site observation
RECRUITING
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)NCT06585787 · 2024-09-26 · 1 site observation
RECRUITING
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLCNCT06216301 · 2024-07-31 · 1 site observation
RECRUITING
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)NCT05485961 · 2024-04-27 · 1 site observation
RECRUITING
Impact of Sleep-Disordered Breathing Management in Systemic Hypertension Control: METASLEEP ProjectNCT05986487 · 2024-04-16 · 1 site observation
RECRUITING
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)NCT05512364 · 2023-12-15 · 1 site observation
RECRUITING
Study of Personalized Allocation of Defibrillators in Non-ischemic Heart Failure (SPANISH-1)NCT06055504 · 2023-09-06 · 1 site observation
RECRUITING
OSIREAL - Osimertinib RWE on EGFRm NSCLC in SpainNCT06068049 · 2023-07-28 · 1 site observation
RECRUITING
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)NCT05980949 · 2023-07-11 · 1 site observation
RECRUITING
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951 · 2023-03-31 · 1 site observation
RECRUITING
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast CancerNCT05306041 · 2023-01-02 · 1 site observation
RECRUITING
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsNCT05232916 · 2022-12-16 · 1 site observation
RECRUITING
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654 · 2022-12-12 · 1 site observation
RECRUITING
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in EuropeNCT05363319 · 2022-10-26 · 1 site observation
RECRUITING
Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive PollenNCT04891237 · 2021-06-14 · 1 site observation
RECRUITING
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.NCT02102165 · 2014-04-01 · 1 site observation
RECRUITING
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or ObesityNCT07861100 · 2026-10-26 · 1 site observation
NOT_YET_RECRUITING
Optimizing the Use of Aspirin for the Prevention of PreeclampsiaNCT07665853 · 2026-07-01 · 1 site observation
NOT_YET_RECRUITING
LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)NCT06558799 · 2024-10-14 · 1 site observation
TERMINATED
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's DiseaseNCT06544616 · 2024-07-22 · 1 site observation
ACTIVE_NOT_RECRUITING
Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain.NCT06321731 · 2024-07-02 · 1 site observation
COMPLETED
Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental DopplerNCT05284474 · 2024-06-03 · 1 site observation
NOT_YET_RECRUITING
A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC PopulationNCT05708235 · 2024-04-01 · 1 site observation
ACTIVE_NOT_RECRUITING
ABG+/GarlACE Effects on Cardiovascular Risk Factors in Subjects With Grade I HypertensionNCT06264622 · 2024-02-26 · 1 site observation
UNKNOWN
Application of a Protocol of Personalized Medicine in Patients With Type 2 Diabetes Mellitus and Multiple Doses of Insulin in Routine Clinical CareNCT06148376 · 2023-12-01 · 2 site observations
COMPLETED
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose WeightNCT06066528 · 2023-11-27 · 1 site observation
COMPLETED
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)NCT05952557 · 2023-10-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Effects of Table Tennis for People With Parkinson's DiseaseNCT06444685 · 2023-10-01 · 1 site observation
UNKNOWN
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+PertuzumabNCT05744375 · 2023-09-28 · 1 site observation
TERMINATED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.